Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Operating Expenses (2022 - 2025)

TriSalus Life Sciences' Operating Expenses history spans 4 years, with the latest figure at $6.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 11.48% year-over-year to $6.7 million; the TTM value through Dec 2025 reached $36.4 million, up 2.16%, while the annual FY2025 figure was $36.4 million, 2.16% up from the prior year.
  • Operating Expenses reached $6.7 million in Q4 2025 per TLSIW's latest filing, down from $11.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $18.5 million in Q3 2023 to a low of $288273.0 in Q2 2022.
  • Average Operating Expenses over 4 years is $9.1 million, with a median of $9.1 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: soared 3987.1% in 2023, then tumbled 51.72% in 2024.
  • A 4-year view of Operating Expenses shows it stood at $10.3 million in 2022, then surged by 33.49% to $13.8 million in 2023, then tumbled by 44.75% to $7.6 million in 2024, then fell by 11.48% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Operating Expenses are $6.7 million (Q4 2025), $11.8 million (Q3 2025), and $9.6 million (Q2 2025).